Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies

Current Opinion in Investigational Drugs

Volumn 11, Issue 11, 2010, Pages 1207-1210

  Pearse, Damien ^a   Jarnagin, Kurt ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETHRIN; CYTOKINE ANTIBODY; CYTOKINE RECEPTOR ANTAGONIST; ERYTHROPOIETIN; FASUDIL; GLUCOCORTICOID; INDOMETACIN; METHYLPREDNISOLONE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

BRAIN DYSFUNCTION; BRAIN INJURY; BRAIN VASOSPASM; CENTRAL NERVOUS SYSTEM FUNCTION; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; EARLY INTERVENTION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INNATE IMMUNITY; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; PNEUMONIA; QUALITY OF LIFE; REVIEW; SPINAL CORD INJURY; TRAUMATIC BRAIN INJURY;

EID: 78650385666     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. McDonald JW, Sadowsky C: Spinal cord injury. Lancet (2002) 359(9304):417-425.
2. Thuret S, Moon LD, Gage FH: Therapeutic interventions after spinal cord injury. Nat Rev Neurosci (2006) 7(8):628-643.
3. Blight AR: Cellular morphology of chronic spinal cord injury in the cat: Analysis of myelinated axons by line-sampling. Neuroscience (1983) 10(2):521-543.
4. Fehlings MG, Tator CH: The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp Neurol (1995) 132(2): 220-228.
5. Bracken MB, Shepard MJ, Collins WF Jr, Holford TR, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon JC, Marshall LF, Perot PL et al: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-Year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg (1992) 76(1):23-31.
6. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloë V et al: Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial. Lancet (2004) 364(9442):1321-1328.
7. Sorrells SF, Sapolsky RM: An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun (2007) 21(3):259-272.
8. Guth L, Zhang Z, DiProspero NA, Joubin K, Fitch MT: Spinal cord injury in the rat: Treatment with bacterial lipopolysaccharide and indomethacin enhances cellular repair and locomotor function. Exp Neurol (1994) 126(1):76-87.
9. Slavik RS, Rhoney DH: Indomethacin: A review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients. Neurol Res (1999) 21(5):491-499.
10. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W et al: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med (2000) 6(7):797-801.
11. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA (1996) 93(24):14014-14019.
12. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA (1999) 96(23):13496-1500.
13. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol (2001) 166(12):7527-7533.
14. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol (2004) 3(12):744-751.
15. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, Brines M: Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA (2002) 99(14):9450-9455.
16. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP: Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol (1999) 127(2):482-488.
17. Pearse DD, Chatzipanteli K, Marcillo AE, Bunge MB, Dietrich WD: Comparison of iNOS inhibition by antisense and pharmacological inhibitors after spinal cord injury. J Neuropathol Exp Neurol (2003) 62(11):1096-1107.
18. Mueller BK, Mack H, Teusch N: Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov (2005) 4(5):387-398.
19. Baptiste DC, Tighe A, Fehlings MG: Spinal cord injury and neural repair: Focus on neuroregenerative approaches for spinal cord injury. Expert Opin Investig Drugs (2009) 18(5): 663-673.
20. de Rivero Vaccari JP, Lotocki G, Alonso OF, Bramlett HM, Dietrich WD, Keane RW: Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab (2009) 29(7):1251-1261.
21. Pearse DD, Pereira FC, Marcillo AE, Bates ML, Berrocal YA, Filbin MT, Bunge MB: cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med (2004) 10(6):610-616.
22. McCoy MK, Tansey MG: TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 5:45.
23. de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD, Keane RW: A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci (2008) 28(13):3404-3414.
24. Atkins CM, Oliva AA Jr, Alonso OF, Pearse DD, Bramlett HM, Dietrich WD: Modulation of the cAMP signaling pathway after traumatic brain injury. Exp Neurol (2007) 208(1):145-158.
25. Schaal SM, Garg MS, Golshani R, Ghosh M, Lovera L, Lopez M, Patel M, Louro J, Puentes R, Sanchez AR, Andrade CM et al: Targeting phosphodiesterase-4 after spinal cord injury using pharmacological and molecular approaches. J Neurotrauma (2008) 25(7):Abs P297